Glenmark Pharmaceuticals Ltd. (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Clindamycin Phosphate Foam, 1%, the generic version of Evoclin®1 Foam, 1%, of Mylan Pharmaceuticals Inc.
According to IQVIATM sales data for the 12 month period ending July 2021, the Evoclin® Foam, 1%, market2 achieved annual sales of approximately USD 12.0 million*.
Glenmark's current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 47 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
This story is provided by PRNewswire.will not be responsible in any way for the content of this article. (ANI/PRNewswire)
( With inputs from ANI )
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor